What this phase means
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Tirzepatide, or Semaglutide. The registry lists allocation as randomized. The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes.
They plan to enroll about 80 people at Hamilton. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Mechanisms of Weight Loss Due to Dual GIP GLP-1 Receptor Agonism With Tirzepatide Compared to Semaglutide: A Randomized Controlled Trial
Interventions: Tirzepatide, Semaglutide
Primary outcome (registry wording): 24-hour Energy Expenditure Measured Using Whole Room Indirect Calorimetry